Q2 Net Loss Widens, Going Concern Warning Issued Amidst Major Subsidiary Divestiture
ISCO has more than doubled off its 52-week low of $0.07 on light trading volume (0.2× avg).
Summary
International Stem Cell Corp. reported a significantly wider net loss for Q2 2026 and reiterated its 'going concern' warning, while confirming the previously announced $25 million sale of its LCT subsidiary, which will substantially reduce its operations.
Key Events · Earnings and Guidance · ISCO
-
Net Loss More Than Doubled in Q2
The company reported a net loss of $291 thousand for the six months ended June 30, 2026, a significant increase from a $127 thousand loss in the same period last year. For Q2 alone, the company swung to a $71 thousand loss from a $129 thousand income in Q2 2025.
-
Going Concern Warning Reiterated
Management explicitly stated substantial doubt about the company's ability to continue as a going concern, citing insufficient cash to sustain operations for at least 12 months without additional financing or maturity extensions.
-
LCT Subsidiary Sale Confirmed
As a subsequent event, the company confirmed the sale of its Lifeline Cell Technology (LCT) subsidiary for $25.0 million on July 10, 2026. This divestiture, while providing cash, will 'substantially reduce' the company's operations and revenue streams, leaving it heavily reliant on remaining business lines.
-
High Customer Concentration Risk
One customer accounted for 61% of consolidated product sales for Q2 2026 and 64% of accounts receivable as of June 30, 2026, posing a significant concentration risk to the remaining business.
Analysis · ISCO · Life Sciences
This quarterly report reveals a significant worsening of financial health, with net losses more than doubling year-over-year for the six-month period. The company explicitly reiterates its 'going concern' warning, indicating insufficient cash to sustain operations for the next 12 months without additional financing. While the subsequent sale of the Lifeline Cell Technology (LCT) subsidiary for $25 million provides a critical cash infusion, it also means the company will be 'substantially reduced' and 'heavily dependent on its remaining business lines,' fundamentally altering its operational profile. This divestiture, though a survival measure, highlights the company's distress and introduces new risks related to its future viability as a smaller entity with high customer concentration.
At the time of this filing, ISCO was trading at $0.31 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.5M. The 52-week trading range was $0.07 to $0.48. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.